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ABSTRACT 
The therapeutic goal of cancer treatment is to trigger selective cell death in cancer cells. To 
eliminate cancerous cells effectively, the anti–cancer drugs must be targeted to the affected 
cells. However, anti–cancer drugs are often distributed non–specifically giving rise to 
systemic toxicities and other adverse effects. Cancer specific peptides are useful cancer 
targeting agents that can be used for the targeted delivery of anti-cancer drugs. Several cancer 
targeting peptides and some of their corresponding protein targets have been identified. 
Previous work investigated the specific binding of five of these peptides (p.C, p.H, p6.1, 
Frop-1 and p.L) conjugated to fluorescent nanoparticles (quantum dots) to a panel of human 
cell lines, which included four cancerous cell lines (Caco-2, HeLa, HT29 and HepG2) and 
one non-cancerous cell line (KMST-6). Flow cytometry showed that the p.L peptide 
preferentially bind to HT29 cells; suggesting that the expression levels of the target for the 
p.L peptide are higher in these cells.  
The objective of this study was to make use of target specific functionalised quantum dots 
(QDs) to deliver Second mitochondria-derived activator of caspases/ Direct AIP binding 
protein with low PI (Smac/DIABLO) to HT29 cells with the aim of enhancing the effects of 
pro-apoptotic drugs. Smac/DIABLO is a pro-apoptotic peptide that is able to interact with 
inhibitor of apoptosis proteins (IAPs), thereby inducing pro-apoptotic signalling. 
Methodology: CdSe/ZnS core-shell QDs were synthesised using the one-pot synthesis 
method. These QDs were characterised using photoluminescence (PL) spectroscopy, high 
resolution transmission electron microscopy (HR-TEM) and energy dispersive x-ray 
spectroscopy (EDS). The CdSe/ZnS core-shell QDs were solubilised with L-cysteine (Cys-
QDs). The Cys-QDs were bi-conjugated to the p.L peptide and Smac peptide using 1-ethyl-3-
(30-dimethylamino) carbodiimide (EDC) chemistry. Cultured HT29 cells were exposed to the 
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QD peptide bi-conjugates and fluorescence microscopy was employed to assess targeting and 
internalisation. The cytotoxicity of the QD peptide bi-conjugates in combinatorial treatment 
with ceramide was evaluated using the WST-1 Cell Proliferation assay. A commercially 
available QD with similar chemistry was used to carry out a comparative study to relate the 
efficiency of the in-house synthesized QD.  
This study demonstrated that green fluorescent CdSe/ZnS core-shell QDs were successfully 
synthesised and solubilised. Additionally, the QD peptide bi-conjugates proved to be an 
ineffective combinatorial treatment and consequently, HT29 cells were not sensitised to 
ceramide induced cell death. Finally, the microscopy data suggests that the bi-conjugation 
strategy may have been unsuccessful as demonstrated by no selective targeting to HT29 cells. 
To evaluate the effectiveness of the drug delivery system developed in this study, alternative 
bi-conjugation schemes may be investigated. Although the overall objective was not met, the 
efficiency of the in-house synthesised Cys-QDs in comparison to the standard Qdot525 was 
observed to be of good quality and therefore, may potentially be used in other biological 
applications.  
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Chapter One: Literature Review 
 
1.1.  Introduction 
Mortality tolls presented by cancer are staggering in spite of progressive efforts in 
development of cancer therapies. Globally, annual projections are said to reach 
approximately 16 million new cases by 2020 (Thundimadathil, 2012). Inadequate capabilities 
to direct therapeutic moieties to a specific target site, through minimal interaction with 
healthy cells, largely account for the lack in translating research into clinical practice (Ferrari, 
2005). Since cancer cells are characterised by their ability to proliferate autonomously and 
with time acquire multiple mutations, multidrug resistance is instigated. Consequently, 
current drug treatments are attesting to be less effective and there is therefore an urgency to 
develop improved cancer treatment options (Sumer and Gao, 2008 & Sioud and Mobergslien, 
2012). Nanoparticle delivery systems offer an improved alternative due to their ability to 
interact at the cellular level with a great degree of specificity (Byrne et al., 2008 & Singh and 
Lilard, 2009). To efficiently execute this, a better understanding of cancer growth, structure 
and physiology is required (Steichen et al., 2012). 
 
1.2.  Cancer development  
1.2.1. Tumour physiology 
Cancer may be described as the abnormal growth of cells. Customarily, when a cell 
recognises any sort of impairment to its DNA, repair mechanisms are initiated. However, 
failure to execute this gives rise to genomic instabilities; consequently a cancerous cell is 
formed (Gotter 2009). In the advent of maintaining normal biological processes, cancerous 
cells along with healthy cells grow and divide to form new cells, but normal systematic 
processes often eliminate these cells through programmed cell death/apoptosis. However, 
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cancer cells can acquire mutations resulting in malfunctioned apoptotic signalling and in turn 
the cells escape apoptosis, multiplying unhindered to form tumour masses (Figure 1.1).  Of 
note, is that the replication rates of cancerous cells outcompete that of healthy cells and in so 
doing, prompt a higher demand for nutrient supply; consequently, displacing healthy cells 
(Brannon-Pepppers and Blanchette, 2004 & Steichen et al., 2012). Initial tumour growth 
stages rely on diffusion of nutrients restricting tumour size limit to approximately 2 mm
3
. To 
overcome this diffusion limit, the tumour is required to recruit new blood vessels; and this is 
accomplished through a process called angiogenesis (Danhier et al., 2010 & Steichen et al., 
2012).  
                               
Figure 1.1. Tumour growth from a single cell. A single cancerous cell around 
healthy tissue undergoes replication at a much higher rate than normal cells and 
in so doing, displaces healthy tissue and eventually forming a tumour mass 
(Adapted from Brannon-Pepppers and Blanchette, 2004). 
 
1.2.2. Tumour vasculature 
Angiogenesis comprises the construction of new blood vessels from pre-existing vessels and 
once the tumour reaches its solid size state (2 mm
3
), hypoxia is initiated; subsequently 
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inducing angiogenesis (Danhier et al., 2010). More importantly, the number of endothelial 
cells usually exist in a relatively dormant state, with about 1 in every 10 000 endothelial cells 
subjected to cell division. During angiogenesis, however, the turn-over increases up to 50 
times (Brannon-Pepppers and Blanchette, 2004). Since an adequate blood supply is 
absolutely necessary for tumour growth, blood vessels then rapidly grow, generating a highly 
disorganised and irregular vasculature with some regions rich in blood supply and others low 
in blood supply (Brannon-Peppers and Blanchette, 2004 & Byrne et al., 2008 & Danhier et 
al., 2010). Discrepancies in the vasculature lead to significantly varied degrees of blood flow 
throughout the tumour (Brannon-Peppers and Blanchette, 2004). Furthermore, poor 
vasculature results in generation of dead-ended vessels as a result of incomplete endothelial 
linings, essentially instigating leaky and highly permeable tumour vessels that easily allow 
macromolecules into the tumour interstitium (Steichen et al., 2012 & Yu et al., 2012). The 
combination of the aforementioned factors results in a condition known as the enhanced 
permeability and retention effect (EPR) which is a phenomenon exploited for delivery of 
conventional anti-cancer drugs (Steichen et al., 2013). 
                   
1.3.  Challenges in current cancer therapeutics  
Conventional chemotherapy, was regarded as the most effective and preferred method of 
treatment owing to its extensive success in the killing of rapidly dividing cancer cells. 
However, restricted drug dosage, adverse side effects and systematic toxicities remains a 
concern, since rapidly growing healthy cells are also affected by the non-specific distribution 
of the cytotoxic drugs administered (Wang et al., 2009 & Nguyen, 2011 & Sioud and 
Mobergslien, 2012). Furthermore, challenges presented by cells that have assimilated drug 
resistance; results in significantly poor responses to the chemotherapy. As a consequence, 
cancer cells can continue to proliferate uncontrolled; reassemble tumours and metastasize; 
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resulting in poor prognosis (Sumer and Gao, 2008). In view of this, the therapeutic goal of 
chemotherapy has shifted towards selective and proficient eradication of cancer cells whilst 
preserving healthy cells by using targeted drug delivery systems (Haglund et al., 2009 & 
Sioud and Mobergslien, 2012 & Thundimadathil, 2012). 
 
1.4. Targeted drug delivery systems  
To effectively eliminate cancerous cells with increased efficacy, three essential dynamics 
should be considered; firstly, enhanced selectivity towards the target, secondly, therapeutic 
moieties should be designed in such a way that they are capable of bypassing biological 
barriers and lastly, the therapeutic agent should be capable of selectively killing cancerous 
cells once it reaches the target site (Ferrrari, 2005 & Co et al., 2008). Delivery of therapeutic 
agents to the target site may be accomplished by two modes of action, that is, passive or 
active targeting (Ferrari, 2005 & Wang et al., 2008).  
 
 
Figure 1.2. Passive versus active targeting. (a) Passive targeting relies on leaky 
blood vessels for diffusion of particles to the tumour site, whereas; (b) active 
targeting relies on the targeting moiety to deliver the particles directly to the 
tumour site (Adapted from de Barros et al., 2012). 
 
 
(a) (b) 
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1.4.1. Passive targeting  
Passive targeting is best described as the selective accumulation of drugs or drug delivery 
systems at the tumour site. This approach allows the exploitation of pathophysiological 
opportunities by means of the EPR effect (Vasir et al., 2005; Cho et al., 2008 & Danhier et 
al., 2010). Since cancerous tissues are characterised by defective blood vessels and deficient 
lymph vessels, the targeted drug delivery system permeabilises the tissue with great ease 
(Vasir et al., 2005). In some cases, cancer cells overexpress enzymes that are essential for 
metastasis, for example, matrix metelloproteinases (MMPs) (Wang et al., 2008). Based on 
this concept, Wang et al., (2008) developed a tumour activated pro-drug treatment, in which a 
nanoparticle was attached to doxorubicin (DOX) through albumin and an MMP-2 specific 
peptide. Upon successful cellular uptake, the conjugated MMP-2 specific peptide was 
cleaved by intracellular MMP-2, rendering the DOX activated and therefore able to exert 
anti-cancer activity (Wang et al., 2008). Although passive targeting appears efficient, 
specificity remains a challenge. Furthermore, the use of the EPR effect may not be a 
practicable approach in all tumour types; since the degree of cell membrane penetrability 
differs between tumour type and stage. To overcome this limitation, the use of a targeting 
ligand as an amended alternative had been applied (Cho et al., 2008).  
 
1.4.2. Active targeting  
Active targeting relies on the generation of a ternary structure consisting of a drug carrier, an 
active chemotherapeutic drug and a targeting moiety capable of binding to surface proteins of 
cancerous cells that are either uniquely expressed or overexpressed in cancer cells as 
compared to normal cells (Cho et al., 2008 & Danhier et al., 2010). An example of this nature 
is the use of monoclonal antibodies (mAb’s) bi-conjugated to an anti-cancer drug, known as, 
Gefitinib (Abou-Jawde et al., 2003). This FDA approved targeted cancer treatment exerts its 
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effect by blocking epidermal growth factor receptors and tyrosine kinase activity for 
advanced non-small cell lung cancer (Brannon-Peppers and Blanchette, 2004). However, the 
use of mAb’s presents a number of challenges, one of which restricts their in vivo application, 
since repeated administration may induce an immune response that may in turn promptly 
clear the immunoconjugates from the bloodstream (Vasir et al., 2005). Alternative strategies 
to circumvent current limitations using antibodies are under way, but taking this limitation 
into account, the targeting moiety is particularly important for cellular internalisation and 
effective transportation of the drug to the tumour site (Figure 1.2) (Byrne et al., 2008). 
Therefore, in the advent of establishing efficient delivery of therapeutic agents into cancerous 
cells, various delivery agents have been explored for targeted delivery; of which cancer 
targeting peptides have demonstrated to be the most promising non-immunogenic agents 
(Shadidi and Sioud, 2003). 
 
1.5.  Cancer specific peptides as useful targeting agents  
1.5.1. Why peptides? 
The most popular molecular targeting agents used in the past, were mAb’s, however, mAb’s 
are extensively limited by non-specific localisation due to low internalisation efficacy as a 
result of high molecular weight (Shadidi and Sioud, 2003 & Li and Cho, 2011) and uptake by 
the mononuclear phagocyte system (Li and Cho, 2011). The cellular digestion process serves 
to break down any potential pathogens prior to accessing the cell. During endocytosis, a small 
part of the cells’ outer membrane gets pinched off within the cell, forming a vesicle 
containing the potentially pathogenic material. These vesicles then fuse with intrinsic 
degradative material which determines the fate of the endocytosed material (Nichols and Bae, 
2012). In this respect, the application of small peptides as an alternative targeting agent 
emerged to circumvent limitations presented by mAb’s (Shadidi and Sioud, 2003). 
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Advantages demonstrated by peptide-based targeting include the generation of high-affinity 
sequences that are easy to generate using combinatorial screening and easy to conjugate to 
their counterparts (Jaracz et al., 2005). The small size of peptides, usually less than 50 amino 
acids in length, permits a good degree of tissue penetrability, therefore highlighting them as 
ideal drug carriers to the tumour site (Shadidi and Sioud, 2003 & Li and Cho, 2012). 
Additionally, small peptides as targeting agents have demonstrated a considerable level of in 
vivo stability (Jaracz et al., 2005 & Li and Cho, 2012) and contrary to mAb’s, peptides are 
virtually undetectable by the immune system and are therefore expected to induce minimal, if 
any, side effects (Shadidi and Sioud, 2003).  
 
1.5.2. Development of targeting peptides against cancer gene expression patterns 
Genetically, cancer cells uniquely express a distinguishable pattern of genes as compared to 
healthy cells. This has been validated by high throughput technologies used to determine 
cancer type gene expression configurations. Subsequently, this has led to the discovery of 
very promising biomarkers for cancer-type specific targeting (Shadidi and Sioud, 2003). 
These biomarkers include cellular surface proteins, some having the ability to interact with 
the cancer specific peptides in a drug delivery system and subsequently subjected to receptor 
mediated endocytosis, and in so doing create a platform for drug delivery (Svensen et al., 
2012).  
 
1.5.3. The identification of targeting peptides 
Cancer specific peptides have been identified using phage display peptide libraries (Sioud 
and Mobergslien, 2012 & Svensen et al., 2012). This approach involves screening virtually 
all possible short peptide sequences against identified cell surface proteins or cancer cells. 
Table 1.1 lists some cancer specific peptides identified by this technique.  
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Table 1.1. Cancer specific peptides identified by phage display libraries 
Peptide ligand Peptide sequence Cellular target Reference  
Surface 
immunoglobulin 
IELLQAR E-Selectin Fukuda et al., 
2000 
Cancer cell surface KCCYSL Her-2 tyrosine kinase 
type 1 receptor 
Karasseva et al., 
2002 
 LTVSPWY Human breast cancer 
cells 
Shadidi and 
Sioud, 2003 
 CVFXXXYXXC Prostate specific antigen Wu et al., 2000 
Vasculature  CTTHWGFTLC MMP-2 and MMP-9 Koivunen et al., 
1999 
 
Often, the selection of cancer specific peptides is based on their interaction with cell surface 
proteins involved in biological functions, for example, the family of epidermal growth factor 
receptors (EGFR) which is known to be overexpressed in a number of tumour types (Shadidi 
and Sioud, 2003 & Steichen et al., 2013). The epidermal growth factor receptor type 2 (erbB-
2) tyrosine kinase is a receptor whose biological functions are implicated in tumour cell 
survival, proliferation and metastases. The most emphasised area of concern with erbB-2 
overexpression is associated with activation of downstream signalling pathways that promote 
cell survival (Wang et al., 2005). One such example is Akt, a serine/threonine kinase (Kim et 
al., 2005 & Wang et al., 2005 & Normanno et al., 2006) which upon activation, exerts its 
anti-apoptotic effects by phosphorylating two kinds of targets, (1) apoptosis regulatory 
proteins, such as caspase 9 and/or (2) substrates that indirectly inhibit apoptosis (Wang et al., 
2005). Furthermore, erbB-2’s overexpression and activation has been shown to induce drug 
resistance and serve as a poor prognostic marker. Cancer specific peptides that are able to 
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bind erbB-2, can block signalling through this pathway, thus providing a promising avenue in 
cancer therapy since it’s overexpression has been observed in approximately 30% of breast 
cancer cell lines and is associated with poor prognosis in ovarian, colon and bladder cancers 
(Shadidi and Sioud, 2003 & Xu et al., 2005). Markedly, non-peptide small EGFR/erbB-2 
molecule inhibitors have advanced to clinical trials, however, with a low degree of success. 
Alternative potent inhibitors of EGFR/erbB-2 are therefore required. In this respect, a cancer 
specific peptide presents itself as an ideal possibility (Xu et al., 2005). 
 
1.5.4. The LTVSPWY peptide  
LTVPSWY (denoted as p.L), a heptapeptide identified by Shadidi and Sioud (2002) has been 
shown to target and inhibit erbB-2 gene expression by selective delivery of an antisense 
phosphorothioate oligonucleotide to erbB-2 positive tumour cells (Shadidi and Sioud, 2002). 
It was then demonstrated that the p.L peptide bi-conjugated to the pro-apoptotic α-tocopheryl 
succinate (α-TOS) induced a significantly higher degree of apoptosis in erbB-2 positive 
breast cancer cells than untargeted α-TOS (Wang et al., 2007). In another study, the p.L 
peptide was used to deliver the pro-apoptotic peptide (KLAKLAK)2 to breast cancer cells and 
selectively kill them (Sioud and Mobergslien, 2012). Furthermore, the p.L peptide has been 
shown to be internalised by SKBR3 (Shadidi and Sioud, 2002), MDA-MB-453, MDA-MB-
231 and MC7 breast cancer cells (Sioud and Mobergslien, 2012) as well as SKOV-3 human 
ovarian carcinoma cells (Jie et al., 2012). Since the p.L peptide facilitates targeting and 
internalisation in a number of cancer cell lines, it has emerged as a favourable candidate for 
peptide-directed delivery of therapeutic agents to erbB-2 expressing cell lines (Wang et al., 
2007 & Haglund et al., 2009 & Jie et al., 2012 & Sioud and Mobergslien, 2012).  
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1.6.  Cancer and apoptosis 
1.6.1. The role of apoptosis in cancer progression 
Cancer development and progression is allied to abnormalities in biochemical pathways (Fry 
and Vassiley, 2005). ErbB-2 overexpression in cancer cells is associated with one of these 
pathways, namely, the apoptotic signalling pathway (Wang et al., 2005). Apoptosis may be 
defined as a highly regulated form of cell death (Wang et al., 2005 & Kroemer et al., 2005 & 
Rastogi et al., 2009). Apoptotic cells are characterised by morphological changes such as cell 
shrinkage, chromatin consendation and DNA fragmentation and subsequent removal by 
phagocytosis (Narula et al., 1996 & Gewies 2003).  
The fundamentals of apoptosis are characterised and executed by cysteine aspartic acid-
specific proteases (or Caspases) (Fulda and Debatin, 2006) which are synthesised as pro-
enzymes and generally occur in cells in an inactive form, i.e. as a pro-caspase. Upon 
activation, caspases cleave several substrates, activate other pro-caspases; and in doing so, 
stimulate the protease cascade by magnifying apoptosis signalling ultimately leading to cell 
death (Rastogi et al., 2009). Caspases are characterised based on their role in the apoptotic 
pathway, i.e. initiator caspases (which initiate disassembly in response to apoptotic stimuli, 
e.g. caspase 2, 8, 9 and 10) or effector caspases (which has direct function in disassembly of 
cells, e.g. caspase 3, 6 and 7) (Gill et al., 2006 & Rastogi et al., 2009). Caspase activation 
occurs in response to one of two well defined apoptotic pathways, i.e. the extrinsic pathway 
or the intrinsic pathway as seen in Figure 1.3 (Fulda and Debatin, 2006).  
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Figure 1.3. The two pathways of apoptosis. The death receptor pathway is 
facilitated by death receptors that recruit death domain adaptor molecules to form 
a death inducing signalling complex to activate caspase 8/10 and in turn 
downstream caspases. However, the mitochondrial pathway is initiated in 
response to cellular stress. Subsequently, pro-apoptotic proteins are released from 
the mitochondria and activate caspase 9 and in turn downstream caspases (Fischer 
and Schulze-Osthoff, 2005). 
 
 
1.6.2. Apoptosis pathways 
1.6.2.1.  The Extrinsic pathway 
The extrinsic pathway is initiated by means of death receptor signalling, across the cell 
membrane, in which the death receptors bind a ligand. Subsequent recruitment of death 
domain adaptor molecules occurs, leading up to formation of a death inducing signalling 
complex (DISC) which in turn activates pro-caspase 8/10 and eventually resulting in cell 
death or activation of the intrinsic pathway (Scaffidi et al., 1998 & Gill et al., 2006 & Fulda 
and Debatin, 2006 & Rastogi et al., 2009).  
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1.6.2.2.  The Intrinsic pathway 
The intrinsic pathway is initiated and regulated by the mitochondria (Gill et al., 2006). This 
pathway is prompted by various cytotoxic stimuli such as DNA damage, defects in the cell-
cycle check point and loss of survival factors which ultimately lead to mitochondrial damage 
(Wang and El-Deiry, 2003 & Gill et al., 2006). Consequently, B-cell lymphoma 2 associated 
X protein (Bax) expression is upregulated and/or B-cell lymphoma 2 (Bcl-2) expression is 
downregulated. The outer membrane of the mitochondria is then permeabilised, inducing the 
release of pro-apoptotic agents into the cytosol, i.e. cytochrome c, Second mitochondria-
derived activator of caspases/ Direct AIP binding protein with low PI (Smac/DIABLO) and 
apoptosis inducing factor (AIF) which then promotes caspase activation and allows for 
execution of cell death (Figure 3) (Fulda and Debatin, 2006; Gill et al., 2006 & Rastogi et al., 
2009 & Wang et al., 2011). 
 
1.6.3. Pro-apoptotic agents as anti-cancer drugs  
In light of the aberrant regulatory apoptotic signalling pathways, numerous components along 
the pathways elicit a targeting prospect which would facilitate the treatment of cancer. From 
the aforementioned, overexpression of erbB-2 as an example and other cancer cell surface 
receptors alike would provide a preparatory phase in an active targeted drug delivery system 
(Wang et al., 2005). Additionally, designing agents that are able to exert inhibitory effects on 
anti-apoptotic proteins, such as, IAPs in cancer cells provides the second phase of targeting, 
in that it could enhance the efficiency of current chemotherapeutic drugs at lower dosages 
(Arnt and Kaufmann, 2003 & Wang et al., 2005).  
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1.7.  Smac/DIABLO: a pro-apoptotic agent 
1.7.1. Smac/DIABLO  
Smac/DIABLO is a pro-apoptotic protein secreted from mitochondria in response to several 
apoptogenic signalling (Martinez-Ruiz et al., 2008). The wild-type Smac/DIABLO protein is 
239 amino acids in length upon synthesis in the mitochondria; with the first 55 amino acids of 
the NH2-terminal identified as the mitochondrial-targeting sequence (MTS) (Chai et al., 2000 
& Wu et al., 2000 & Shiozaki and Shi, 2004). In the event of apoptotic stimuli, the MTS is 
cleaved by post-translational modifications and subsequently a tetrapeptide motif (Ala-Val-
Pro-Ile) is exposed to allow interaction between Smac/DIABLO and IAPs (Wu et al., 2000 & 
Gao et al., 2007 & Martinez-Ruiz et al., 2008). Several studies have demonstrated that the 
interaction between Smac/DIABLO and IAPs occurs with the baculoviral IAP repeat (BIR) 
domain (Martinez-Ruiz et al., 2008).  
 
1.7.2. Smac/DIABLO association with Inhibitors of apoptosis proteins 
The IAP family of proteins is characterised based on its apoptosis suppressor effect 
(Wilkinson et al., 2004) rendered by their BIR domain (Deveraux and Reed, 1999 and Arnt et 
al., 2002). A total of three tandem copies (BIR1, BIR2 and BIR3) of this domain may occur 
within the IAP proteins (Deveraux and Reed, 1999). The IAP family of proteins comprises of 
eight human analogues of which X-linked IAP (XIAP), cellular IAP1 (cIAP1) and cIAP2 
show the greatest degree of structural homology (Arnt et al., 2002) and are well characterised 
as having direct caspase inhibitory activity (Deveraux and Reed, 1999; Wilkinson et al., 2004 
& Fulda, 2009). Furthermore, it has been shown that increased expression of XIAP induces a 
protective effect against apoptosis in cancer cells (Holcik et al., 2003). This inhibitory effect 
is exerted by binding of the BIR domain to target caspases in such a way that upstream amino 
acids of the caspase active site are eclipsed; consequently preventing caspase activation (Wei 
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et al., 2008). This in turn prompts the degradation of the caspases by the proteosome, thereby, 
inhibiting apoptosis (Martinez-Ruiz et al., 2008). It is important to note that in mammalian 
systems, different IAPs exert their anti-apoptotic effects on caspases, differently. For 
example, IAPs may compete with the apoptosis protease activating factor 1 for binding to 
pro-caspase 9, thus obstructing the formation of the apoptosome (Wei et al., 2008). However, 
Smac/DIABLO release from the mitochondria in response to apoptotic stimuli takes on an 
IAP antagonistic role by disrupting interaction between IAP’s and the corresponding caspases 
(Arnt and Kaufmann, 2003). Structural analysis (Figure 1.4) has demonstrated that 
Smac/DIABLO associates with IAP’s at the BIR3 domain of XIAP by means of its’ N-
terminal AVPI motif (Wu et al., 2000).  
 
 
 
Figure 1.4. Structural analysis of the binding interface between 
Smac/DIABLO and the BIR3 domain of XIAP. The first 4 amino acids of 
Smac/DIABLO’s N-terminus fits into the binding groove of XIAP’s BIR3 
domain. The blue and white regions signify greatest and slightest hydrophobic 
surfaces, respectively and the N-terminal of Smac is depicted in green. (Adapted 
from Wu et al., 2000). 
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XIAP has three BIR domains and is regarded as the most powerful endogenous IAP, having 
very high affinity to caspases (Wei et al., 2008). The BIR2 and BIR3 domains display 
specific binding and inhibitory properties against caspase 3 and 7 (Takeuchi et al., 2005 & 
Tamm et al., 2007). In the case of caspase 9 inhibition, it has been shown that BIR3 and 
RING domains are required (Deveraux and Reed, 2000). Usually, the BIR3 domain would 
form a heterodimer with the monomeric and active form of caspase 9; however, no physical 
binding to caspase 9 active site occurs (Wei et al., 2008). This results in the prevention of 
caspase 9 dimerization and also holds it in an inactive structural conformation, thereby, 
inhibiting downstream apoptotic signalling (Shiozaki and Shi, 2004 & Wei et al., 2008). 
Caspase 9 possesses an IAP binding tetrapeptide motif, Ala-Thr-Pro-Phe (Srinivasula et al., 
2001). If pro-caspase 9 is not proteolytically processed, it is unable to stably complex with 
IAPs, however, in the reverse scenario; this motif is exposed and becomes easily accessible 
for interaction with XIAP (Shiozaki and Shi, 2004). In the event of apoptosis, the mature 
form of Smac/DIABLO released from the mitochondria uses a similar tetrapeptide motif 
(Ala-Val-Pro-Ile) to competitively bind XIAP, and thus interfere with the XIAP-caspase 9 
complex and exert a pro-apoptotic effect (Shiozaki and Shi, 2004 & Wu et al., 2008). Based 
on this interaction, Smac/DIABLO agonists are considered to be co-anti-cancer therapeutic 
agents augmenting well-defined chemotherapeutic drugs (Arnt et al., 2002 & Fandy et al., 
2008). 
 
1.7.3. The application of Smac/DIABLO in the treatment of cancer 
Smac/DIABLO as well as Smac-derived short peptides have been demonstrated to enhance 
the anti-cancer activity of some drugs that induce apoptosis in cancer cells (Chai et al., 2000 
& Arnt and Kaufmann, 2003 & Martinez-Ruiz et al., 2008 & Lu et al., 2011). Several studies 
have been carried out to demonstrate the sensitisation of cancer cells to a panel of pro-
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apoptotic drugs in the presence of overexpressed Smac/DIABLO and/or its peptide 
derivatives (Martinez-Ruiz et al., 2008).  One such example, according to Arnt et al., 2002, is 
Smac/DIABLO. The first 4-8 N-terminal amino acids of Smac/DIABLO was conjugated to 
the penetratin sequence (a carrier peptide that is able to permeabilise the cell membrane) and 
as a result enhanced the degree of apoptosis as well as the long term anti-proliferative effects 
induced by a variety of antineoplastic agents in MCF7 cells. Furthermore, in situ analysis 
revealed that this fusion peptide bound XIAP and cIAP1, subsequently displaces caspase-3 
aggregates; and in so doing enhance the drug-induced caspase activity (Arnt et al., 2002).  
 
Another study demonstrated that the first seven amino acids of the N-terminus of 
Smac/DIABLO sensitised in vivo models of an intracranial malignant glioma xenograft to the 
anti-tumour activity of the tumour necrosis factor-α-related apoptosis-inducing ligand 
(TRAIL) (Fandy et al., 2008). More importantly, only co-treatment of TRAIL and 
Smac/DIABLO peptides completely eliminated tumours and resulted in survival of mice with 
no detectable toxicity. Interestingly, N-terminal Smac/DIABLO peptides only sensitise low 
expressing IAP tumour cells to apoptosis, but are able to induce apoptosis in high expressing 
IAP tumour cells. This reveals that the level of IAP expression in various tumour types 
determines how different tumours will respond to these peptides; and thus, the prospective 
effect of Smac/DIABLO (Fandy et al., 2008). This treatment strategy has the potential to 
reduce anti-cancer dosages whilst increasing intra-cellular concentrations, thereby improving 
patient survival rates (Cho et al., 2008).  
 
In a study conducted by Guo et al., co-treatment of the N-terminal heptapeptide (Smac-7) and 
tetrapeptide (Smac-4) of Smac/DIABLO with either epothilone (Epo) B derivative BMS 
247550 (an antimicrotubule agent) or TRAIL significantly increased the level of apoptosis, 
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observed by PARP cleavage activity exerted on caspase 3. It was also observed that increased 
levels of apoptosis was directly associated with down-regulation of XIAP, cIAP and survivin. 
It was concluded that co-treatment with N-terminal Smac/DIABLO peptides effectively 
enhances the apoptosis signalling and may improve anti-tumour activity of Epo B and TRAIL 
(Guo et al., 2002).  
 
1.8. Nanotechnology-based drug delivery systems 
1.8.1. Nanotechnology 
Taking into account the therapeutic goal of anti-cancer treatment is the selective eradication 
of cancer cells; most conventional anti-cancer drug treatments are ineffective as a result of 
non-specific distribution of the drug (Sinha et al., 2006). Therefore, alternative drug delivery 
methods are required. Nanotechnology has emerged as a promising strategy to develop 
appropriate and efficient drug carriers for targeted drug delivery systems (Yu et al., 2012). 
Nanotechnology is the field of science that relates to technological systems based on small 
sized materials, ranging between 1 - 100 nm. It is this size range that allows the exhibition of 
novel properties in nanomaterials, distinguishing them from bulk materials with respect to 
physical and chemical properties (Cao and Wang, 2011). 
 
Nanoparticles have the ability to enter the smallest capillary vessels and circumvent rapid 
clearance by phagocytes (Cho et al., 2008). Therefore, successfully prolonging their blood 
circulation time and increasing the chances as well as drug load reaching the target site (Cho 
et al., 2008 & Nichols and Bae, 2012). Depending on the size and surface characteristics, 
unmodified nanoparticles are generally seized by the reticuloendothelial system (Cho et al., 
2008). Numerous nanoparticles have successfully been employed in the development of drug 
delivery systems for use in cancer therapy (Table 1.2) (Pal and Nayak, 2010). 
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Table 1.2. Nanoparticle-based delivery systems. 
Nanoparticle-based delivery system Therapeutic application 
Liposomes Controlled and targeted drug delivery  
Targeted gene delivery 
Polymeric Micelles Controlled and targeted drug delivery  
Dendrimers Targeted drug delivery 
Gold nanoparticles Targeted delivery and imaging agent 
QDs Targeting and imaging agent 
Adapted from Pal and Nayak, 2010. 
 
Nanomaterials may be categorised based on quantization effects, i.e. when the charged 
carriers are confined in either one, two or three dimensions. For example, nano-structures 
confined in one dimension, are categorised as two dimensional structures; however, if they 
are confined in two dimensions, they are considered as a one dimensional structure and lastly, 
if confined in three dimensions, they are regarded as zero dimensional structures, which is the 
category into which QDs are defined (Drbohlavova et al., 2009). 
 
1.8.2. QDs 
1.8.2.1.  Optical properties 
QDs are semiconducting colloidal crystalline nanoparticles (Galian and Guardia, 2008). Their 
diameters generally range from 2 - 10 nm in size (Drbohlavova et al., 2009) and are 
characterised based on quantum confinement effects, which is described by the radius of the 
crystalline nanoparticle that approaches values lower than one of the magnitudes illustrated 
by the Bohr radius of electron, hole and exciton, respectively (Chan et al., 1998). As a result 
of size and the corresponding quantum confinement effects, QDs possess unique properties as 
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compared to bulk materials although having the same chemical composition (Mattheakis et 
al., 2004).  
 
With respect to semiconducting material, QDs exhibit useful optical properties which depend 
on the material used, the size of the particles, the size distribution and surface chemistry 
(Mattheakis et al., 2004 & Resch-Genger et al., 2008). These properties include the formation 
of broad absorption spectra which may be described as energy absorption of a photon above 
the semiconductor band gap resulting in formation of an exciton (Michalet et al., 2005). 
Furthermore, radiative recombination of electron-hole pairs in QDs leads to a long 
fluorescence lifetime (20 – 50 ns) of photon emission as compared to conventional 
semiconductors (<10 ns)  (Yoffe, 2001; Gao et al., 2005 & Michalet et al., 2005). 
 
 
1.8.2.2.  QDs versus organic fluorophores 
QDs are widely used for cellular labelling and imaging of tissues and cells using fluorescence 
techniques (Resch-Genger et al., 2008 & Medintz and Mattoussi, 2009). The optical 
properties mentioned above contribute significantly to the advantages offered by QDs as 
compared to conventional fluorophores (Michalet et al., 2005 & Medintz and Mattoussi, 
2009). QDs possess particular photo-physical properties, in particular, high photostability 
which result in preference to conventional organic dyes (Galian and Guardia, 2009). QDs are 
generally synthesised from atoms in group II and IV (Reiss et al., 2009).  Further addition of 
an inorganic shell produces core/shell QDs that have greater quantum yields than the 
uncoated ones (Frasco and Chaniotakis, 2009). To be precise, in QDs, PL is high in the 
visible as well as the near infrared ranges. However, PL for organic dyes is only high in the 
visible range (Resch-Genger et al., 2008). QDs have the ability to gradually increase 
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absorption leading to shorter wavelengths and narrower emission bands. This may be 
manipulated by changing the particle size (Jin et al., 2008 & Galian and Guardia, 2009).  
Variation of size and composition of QDs makes it possible for wavelengths to be tuned from 
blue to near infrared. That is, the emission wavelength may be blue shifted and red shifted by 
smaller and larger QDs, respectively. Organic dyes may only fluoresce at a particular 
wavelength it was designed for (Chan et al., 2002). Furthermore, the increase in fluorescence 
lifetime in QD leads to greater sensitivity. As mentioned earlier, QDs have an advantage in 
relation to photostability; this is made possible as a result of surface passivation, in which 
photo-oxidation may almost be completely suppressed by the inorganic shell coating. This is 
an attractive property for imaging techniques that involves intense laser excitation sources 
especially for long-term imaging (Resch-Genger et al., 2008). The exploration of many 
fundamental biological processes is dependent on the rapid, sensitive and reproducible 
detection of biomolecule interactions and fluorescence techniques are applicable in 
accomplishing these objectives. Since QDs have been shown to possess improved properties 
in comparison to conventional fluorophores, QDs have therefore taken preference in many 
biological applications (Resch-Genger et al., 2008). 
 
1.9.  The application of QDs in targeted drug delivery systems 
1.9.1. Water-soluble QDs 
Most reliable synthesis methods make use of organic solvents for production of highly 
monodispersed and homogenous nanostructures, resulting in the materials requiring 
solubilisation for biological application (Vo-Dinh, 2007). There are two processes to achieve 
biocompatibility for QDs; (1) ligand exchange, which involves native surface ligands being 
substituted with a bi-functional ligand containing an anchoring moiety (e.g. thiol) and a 
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hydrophilic functional group (e.g. –NH2 or –COOH) and; (2) encapsulation of the native 
capping layer using amphilic polymers or silica (Zhang and Clapp, 2011). Once solubilised, 
QDs can be functionalised with biomolecules such as nucleic acids, carbohydrates, proteins, 
lipids and polymers and probed for target delivery, as shown in figure 1.5 (Vo-Dinh, 2007). 
 
                                    
Figure 1.5. Water-soluble CdSe/ZnS QDs functionalised with a targeting 
moiety. (Adapted from Haglund et al., 2009) 
 
1.9.2. Bi-conjugation chemistry  
In order to facilitate the use of a drug delivery system, the respective moieties are required to 
be chemically linked (Hermanson, 2013). This is achieved through the concept of bi-
conjugation, which may be described as the covalent linkage of two or more molecules. 
Several bi-conjugation cross-linkers exist, therefore, choosing the appropriate one relies on 
the chemical groups available on the target molecules (Zhang and Clapp, 2011 & Hermanson, 
2013). 
 
Peptides have amino acids that are joined through the formation of covalent bonds. Each 
amino acid comprises of an amino group (N-terminal) and a carboxyl group (C-terminal) 
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(Hermanson, 2013). The N-terminal of peptides may be coupled to activated carboxylates, 
subsequently yielding amide bi-conjugates. Alternatively, the C-terminal may be exploited by 
bi-conjugation through formation of an amide bond (Hermanson, 2008). EDC is cross-linker 
most often employed to mediate the above described bi-conjugation. EDC is a zero-length 
cross-linker, that is, in the process of conjugation; no additional atoms are incorporated 
(Zhang and Clapp, 2011 & Vashist, 2012). This is advantageous, in that, the introduction of 
foreign structures by other cross-linkers may prompt interference in the function of the 
complexed biomolecule. EDC, therefore, excludes the susceptibility to any form of cross-
reactivity by forming directly complexed bi-conjugates (Hermanson, 2008). Other methods of 
conjugation exist, such as the use of thiolated peptides which can directly attach to the ZnS 
coated QDs induced by the affinity of thiols for Zn molecules (Zhang and Clapp, 2011) or 
adsorption of engineered proteins, for example proteins with His-tags (Mattoussi et al., 
2000). 
 
1.9.3. Peptide directed QDs 
Work done by Haglund et al., demonstrated the successful targeting to SkBR3 breast cancer 
cells using QDs bi-conjugated to the p.L peptide. This work illustrated the twofold 
functionality of the targeting peptide, that is, the QDs reaching the cell membrane and being 
internalised, as observed by the fluorescence of the QDs (Haglund et al., 2009). Since the in 
vitro experiments showed success, the p.L peptide was then applied to an in vivo mouse 
model, having a human SkBR3 tumour xenograft. The QD/p.L peptide bi-conjugate was then 
injected into the tails of the mice and effectively targeted to the tumour mass (Haglund et al., 
2009).  
In another study by Shi et al., arginine-glycine-aspartic acid (RGD) peptides were bi-
conjugated to QDs and used to target integrin ανβ3 which are crucial vehicles for metastatic 
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cancers (Felding-Habermann, 2000 & Shi et al., 2006). The RGD motif was exploited for its 
high selectively and affinity against integrin ανβ3. Also, important to note, integrin ανβ3 is 
known to be significantly upregulated in tumour tissues, but not in healthy tissue (Bentolila et 
al., 2000). Using this model, several studies of in vivo tumour targeting and imaging were 
reported (Chen et al., 2004 & Cai et al., 2006 & Cai et al., 2007).  
 
1.9.4. Multifunctional QDs for cancer treatment 
The multifunctional capacity of nanoparticles provides unique advantages for cancer 
diagnosis and treatments (Yu and Jon, 2012). The large surface area allows for 
functionalization of the nanoparticles with several ligands, that is, either retaining diagnostic 
or therapeutic properties (Haglund et al., 2009 & Ho and Leong, 2010), presenting the QDs 
as a theranostic (diagnostic and therapeutic) modality (Ho and Leong, 2010). 
 
A successful theranostic QD study presented by Bagalkot et al, (2007), illustrates the 
conjugation of QDs to aptamers and DOX (QD-Apt-DOX). An RNA aptamer was designed 
to target and image prostate-specific membrane antigen (PSMA) expressed in LNCaP cells 
using the fluorescent properties offered by the QDs. The DOX moiety was intercalated within 
the aptamer and used in a fluorescence resonance energy transfer (FRET) based manner. In 
the drug-loading state, the fluorescence of both the QD and DOX were undetectable as a 
result of the aptamer that quenched the fluorescence of the DOX and subsequently DOX 
quenched the fluorescence of the QDs. However, in the drug-release state, DOX is released 
from the QD-Apt conjugate, resulting in the fluorescence of both DOX and the QDs. More 
importantly, the DOX fluorescence could be traced during transportation of the drug 
(Bagalkot et al., 2007). 
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QDs have shown to be excellent imaging agents, for both in vitro and in vivo models. With 
the increasing application of QDs in therapeutic delivery, the potential use of QDs as a 
multifunctional modality is also increasing. However, there are still some controversies 
surrounding the potential cytotoxicity of QDs (Ho and Leong, 2010). 
 
1.9.5. Cytotoxicity of QDs 
QD toxicity is dependent on several factors, including, its size, composition and surface 
modifications (Winnik and Maysinger, 2013). Additionally, toxicity profiles maybe attributed 
to inherent properties of the QDs as well as the environmental conditions (Hardman, 2006). 
Bhatia et al., showed the relationship between cytotoxicity and the surface properties of QDs 
for an in vitro model. It was noted, that the oxidation of the QD surface prompted the reduced 
form of Cd, which in turn resulted in the release of free Cd ions. And the presence of Cd
 
ions 
was strongly correlated to cell death (Bhatia et al., 2004 & Chen et al., 2011). Very important 
to note, each QD retains its own physicochemical properties and therefore, highlights the fact 
that all QDs are not alike, thus their physicochemical properties determine their potential 
cytotoxicity (Hardman, 2006). This was confirmed by several in vitro studies, illustrating that 
certain types of QDs may be toxic (Hoshino et al., 2004 & Lovric et al., 2005). 
 
Most literature alludes to the fact that the dissipation of Cd leads to cytotoxic effects, 
however, chemically capping QDs with inert materials, for example, silica, serves as a good 
measure to avoid cellular toxicities (Gomes et al., 2011).       
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1.10. Objective of this study  
The objective of this study was to develop a multimodal nanoparticle-based targeted drug 
delivery system using peptide directed QDs as an imaging agent and delivery vehicle to 
selectively kill cancer cells using the pro-apoptotic peptide, Smac in combinatorial treatment 
with ceramide. 
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Chapter Two: The synthesis, characterisation and solubilisation of 
CdSe/ZnS core-shell QDs 
2.1. Introduction 
QDs are semiconductor colloidal crystalline nanoparticles with diameters, generally, ranging 
between 2 - 10 nm in size. They are characterised based on quantum confinement effects, 
resulting in QDs possessing unique optical properties as compared to bulk materials (Chan et 
al., 1998 & Mattheakis et al., 2004 & Galian and Guardia, 2008 & Drbohlavova et al., 2009). 
In biological applications, fluorescent colloidal QDs have been reported to retain several 
advantages when compared to conventional organic fluorophores. These include, higher 
photostability, greater quantum yields; size and composition tunable wavelength emissions as 
well as increased fluorescence lifetimes (Chan et al., 2002 & Michalet et al., 2005 & Jin et 
al., 2008 & Resch-Genger et al., 2008 & Galian and Guardia, 2009 & Medintz and 
Mattoussi, 2009). 
It is important to note that biological environments call for specific chemical and optical 
properties of nanoparticles applied to them. Since the photophysical properties of QDs are 
associated with its surface states, it is critical to direct the surface chemistry in such a way 
that biocompatibility, yet desirable optical properties and electronic passivation are retained 
in the aqueous medium (Jamieson et al., 2007 & Zhang and Clapp, 2011). This has been a 
challenge, despite efforts to directly synthesise QDs using aqueous synthetic methods. It 
appears that most aqueous approaches produce moderately stable and low quantum yields. 
Consequently, an organometallic route remains a more reliable synthesis scheme (Zhang and 
Clapp, 2011). 
Synthesis of highly monodispersed and highly fluorescent QDs is most commonly achieved 
at elevated temperatures, using organic solvents, such as trioctylphosphine (TOP) (Vo-Dinh, 
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2007 & Tiwari et al., 2009). Even though QDs are generally synthesised from group II-VI 
atoms, CdSe/ZnS are most often employed in biological applications (Midentz et al., 2005). 
The growth of QD core structure has been reported to occur in two stages, that is, step (1): 
nucleation which is then followed by step (2): Ostwald ripening, described as a mechanism in 
which small particles dissolve and deposit onto larger particles in solution to achieve a more 
thermodynamically stable state (Huy, et al., 2011). To prevent CdSe oxidation or leakage and 
also attain high quantum yield, an inorganic material with a higher band gap is generally 
used, for example, ZnS (Dabbousi et al., 1997).  
 
2.2. Objective of this chapter 
The objective of this chapter was to synthesise and characterise highly monodispersed and 
highly green fluorescent CdSe/ZnS QDs using an organometallic approach and to use the as 
prepared QDs to produce water-soluble L-cysteine capped CdSe/ZnS core-shell QDs to be 
applied in a biological application.  
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2.3. Materials and suppliers  
1-Octadecene         Sigma-Aldrich 
2-Propanol         Sigma-Aldrich  
Acetone         Sigma-Aldrich 
Argon          Afrox 
Cadmium Oxide        Sigma-Aldrich 
Ethanol          Merck  
Hexane         Sigma-Aldrich 
L-cysteine         Sigma-Aldrich 
Liquid Nitrogen        Afrox 
3-Mercaptopropionic acid       Sigma-Aldrich 
Methanol          Merck  
Phosphate buffered saline         Whitehead Scientific 
Oleic acid         Sigma-Aldrich 
Selenium powder        Sigma-Aldrich 
Sodium Hydroxide        Merck 
Sulfur          Sigma-Aldrich 
Trioctylphosphine        Sigma-Aldrich 
Zinc Undecylenate        Sigma-Aldrich 
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2.4. Methods  
2.4.1. The organometallic synthesis of CdSe/ZnS core-shell QDs  
Synthesis of the QDs was performed as described by Boatman and Lisensky, 2005 with 
minimal modifications. All reactions were setup under an inert atmosphere, created by careful 
purging of the system with nitrogen gas (Figure 2.1). All the flasks were sealed with rubber 
septa. A stock solution of the selenium (Se) precursor was prepared prior to synthesis, by 
addition of Se powder (0.2716 g) to 1-octadecene (ODE) (8 ml) and trioctylphosphine (TOP) 
(2 ml) in a two-necked flask. The mixture was heated in a silicon oil bath to 140 
o
C while 
stirring until dissolved to give a clear solution. Meanwhile, the cadmium-oleate precursor was 
synthesised by addition of cadmium oxide (0.110 g) to oleic acid (1 ml) in a three-necked 
flask. The mixture was then heated to 225 
o
C while stirring until complete dissolution of CdO 
with resultant formation of the cd-oleate precursor. The temperature was then lowered to 120 
o
C and 2 ml of previously prepared Se precursor was rapidly injected into the Cd oleate 
mixture. At this point, the colour of the solution changed from clear to yellow. The 
nanoparticles were allowed to grow for 8 min. An aliquot (0.1 ml) was extracted at 8 min and 
dissolved in hexane. Subsequent quenching of the reaction was carried out by placing the 
solution on ice.  
 
The CdSe core nanoparticles were then layered with a zinc sulphide (ZnS) shell. The sulphur 
(S) precursor was prepared by dissolution of S powder (0.138 g) in ODE (9 ml) and TOP (1 
ml) at 140 
o
C, while stirring. This mixture was then allowed to cool down to room 
temperature. The Zn-TOP precursor was prepared by addition of zinc undecylanate powder 
(1.857 g) to ODE and TOP. The Zn-TOP mixture was heated to 140 
o
C while stirring until 
complete dissolution.  
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Figure 2.1. General setup for the organometallic synthesis of CdSe/ZnS core-
shell QDs. 
 
The temperature of the Zn-TOP mixture was then lowered to 90 
o
C. At the same time, the 
CdSe solution was reheated to 90 
o
C. At this point, the TOP-Zn was added and allowed to 
mix for 10 min. Thereafter, the TOP-S was added to the reaction mixture and this was 
followed by growth of the ZnS nanoparticle shell for one hour.  Aliquots (0.1 ml) were 
extracted at 30 min and 60 min and dissolved in hexane. The reaction was then stopped and 
allowed to cool down to room temperature. The CdSe/ZnS quantum dot sample was stored at 
4 
o
C.  
 
2.4.2. Precipitation of the CdSe/ZnS core-shell QDs  
The quantum dot sample generated in Section 2.4.1 was dissolved in a small amount of 
hexane (1 ml). This solution was then transferred to clean 2 ml eppendorf tubes, vortexed and 
centrifuged at 14 500 x g for 10 min. The supernatant from all the eppendorf tubes were 
transferred to a clean glass beaker and the pellets were discarded. Acetone was added to the 
Thermocoupler 
Liquid Nitrogen 
Cold-trap 
Sulfur precursor 
Zinc precursor 
Injection site into 
Cd-oleate complex 
Heating 
mantle 
Selenium precursor 
Condenser 
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supernatant until a cloudy solution was achieved. This solution was then transferred to clean 
2 ml eppendorf tubes, vortexed and centrifuged at 14 500 x g for 10 min. The clear 
supernatant was discarded and a few drops of hexane were added to the pellet in one of the 
eppendorf tubes. This suspension was vortexed and transferred to the next eppendorf. The 
pellets were all collected in this manner until one suspension remained. A few drops of 
acetone were added to the suspension, at this point, the solution became cloudy. The solution 
was vortexed and centrifuged at 14 500 x g for 10 min. The supernatant was discarded and 
the pellet was weighed and stored at 4 
o
C, in the dark, until further use. 
 
2.4.3. Characterisation of CdSe/ZnS core-shell QDs 
2.4.3.1. PL spectroscopy 
The PL spectra were obtained using the HORIBA Nanolog FL3-22-TRIAX spectrometer that 
used a CCD detection system. Dilute solutions of the CdSe/ZnS core-shell QDs in hexane 
were placed in 1 cm quartz cuvettes and their corresponding fluorescence were measured. 
This is a non-destructive technique that can provide information about semiconducting 
material. Upon exposure of the nanomaterial to light, the PL (emitted light) gets stimulated 
by a higher energy than that of the luminescent light and an emission spectrum is formed and 
analysed computationally (Seyhan, 2003). 
 
2.4.3.2. High resolution transmission electron microscopy 
High resolution TEM micrographs were obtained on a field emission TEC NAI F20 TEM 
microscope. One drop of a dilute solution of CdSe/ZnS core-shell QDs in hexane was placed 
onto a copper grid, supported by a thin film of amorphous carbon. This technique uses 
electrons that are shot through the sample at a high acceleration voltage. Changes in the 
electron beam due to scattering discharged by the sample are then measured. This interaction 
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between the electrons and the sample, at that point, produces an image. The difference in 
contrast between the sample and the background Cu grid, provides direct information about 
the nanoparticle morphology (Qi et al., 2001 & Rao and Biswas, 2009). 
 
2.4.3.3. Energy dispersive x-ray spectroscopy 
The EDS spectrum was obtained using a field emission TEC NAI F20 TEM microscope. The 
same samples from Section 2.4.3.2 were used. EDS is a characterisation technique that 
provides an elemental and chemical analysis of the nanomaterial being probed (Rao and 
Biswas, 2009). EDS relies on the unique atomic structure ascribed to every element, in such a 
way that the x-ray spectrum emitted for the different atomic structures, are clearly discernible 
from one element to another. The spectrum is formed by excitation of electrons in the inner 
shell (lower energies). The excited electrons move to a higher energy state, subsequently 
creating vacant shells in the electronic structure of the atoms being probed. Electrons from 
the outer shells (higher energies) replenish the vacant shells; and the difference in energy 
between the higher and lower energy shells are emitted as x-rays. The x-rays are then 
measured by an energy dispersive spectrometer (Russ 1984 & Rao and Biswas, 2009). 
 
2.4.4. Ligand exchange  
The quantum dot pellet generated in Section 2.4.2 was dissolved in a 1.65 mM solution of L-
cysteine (pH 8) and sonicated at 50 W and 60 Hz for 1 min, then placed on ice for 30 sec. 
This was repeated until a 15 min sonication cycle was completed. The water-soluble L-
cysteined capped QDs were stored at 4 
o
C, in the dark, until further use. 
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2.5. Results and discussion 
2.5.1. Synthesis of CdSe/ZnS core-shell QDs 
Highly luminescent and monodispersed CdSe/ZnS core-shell QDs were synthesised using an 
organometallic approach, as described in Section 2.4.1 (Boatman and Lisensky, 2005). CdO, 
Se, Zn undecylated and sulfur powder were used as the source for the Cd, Se, Zn and S 
precursors, respectively. 1-Octadecene (ODE) served as a solvent for the Cd-oleate mixture 
and the ODE/TOP mixtire served as a solvent for the remaining precursors. Oleic acid (OA) 
provided a protective capping layer. It was also selected for its dual function, that is, 
primarily a stabilising ligand for Cd to form a highly reactive Cd-oleate complex. Secondly, 
OA served as an accelerator during the QD core nucleation process (Zou et al., 2010).  
 
2.5.2. Characterisation of CdSe/ZnS core-shell QDs 
2.5.2.1. Introduction 
The unique properties exhibited by nanoparticles and QDs in particular, are attributed to their 
physicochemical properties. Therefore, determining these characteristics plays an important 
role in understanding their behaviour and subsequent application in biological systems 
(Zhang and Clapp, 2011). Since much attention has been drawn to QDs as a result of their 
unique optical properties; from the literature, the most frequently reported characterisation 
techniques employed include (1): UV-Vis spectroscopy to measure absorbance which induces 
the electronic transition from the ground to the excited state and (2): PL spectroscopy to 
measure fluorescence which is when the electronic transition occurs from the excited to the 
ground state. Additionally, transmission electron microscopy (TEM) provides detailed 
morphological information by interrogation of electron diffraction patterns. TEM also serves 
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as a good validation approach for other methods. EDS is another technique employed for 
elemental analysis (Dabbousi et al., 1997 & Boatman and Lisensky, 2005 & Pechstedt et al., 
2010).  
 
2.5.2.2. PL properties of CdSe/ZnS core-shell QDs  
Medintz et al., (2005) and Pong et al., (2008) reported QDs synthesised from CdSe cores 
coated with a ZnS shell, as the best suited QDs for biological applications because the 
chemistry of these QDs are extensively researched and understood. As previously mentioned, 
the ZnS layer serves to (1) passivate the core surface, (2) safeguard it from oxidation, (3) 
inhibit Cd/Se leaching into the buffer solution and (3) improving PL yield. PL spectroscopy 
aids in providing valuable information about the as-synthesised QDs optical properties; 
which in turn helps to interpret whether or not the aforementioned properties were achieved 
(Medintz et al., 2005 and Pong et al., 2008).   
The objective of the synthesis was to obtain green emitting fluorescent nanoparticles. The 
optimised time for the experiments was 8 min which demonstrated sufficient fabrication of 
CdSe cores with wavelength emissions at ~510 nm. This finding agrees with Huy et al., who 
demonstrated that extended QD core growth times induce a decrease in PL intensity (Huy et 
al., 2011). This occurs as a result of particles that are highly susceptible to re-dissolution or 
bleaching prompted by the heat. Figure 2.2 shows the PL spectrum used (1): to investigate 
whether the ZnS was successfully coated onto the CdSe QDs, (2): to define the size 
distribution; and (3): to determine the wavelength emissions of the nanoparticles synthesised 
in Section 2.4.1. 
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Figure 2.2. PL spectra of CdSe core QDs (red), CdSe/ZnS core-shell QDs 
after 30 min (light green), CdSe/ZnS core-shell QDs after 60 min (pink) and 
CdSe/ZnS core-shell QDs after 3 days (dark green). The inset shows a 
schematic diagram of CdSe core QDs before and after coating with ZnS 
(Angell, 2011). 
 
No significant differences were observed between the 30 min and 60 min ZnS coating time 
points. However, a red shift in the emission wavelength from the core to core-shell structure 
(green and pink peaks) was observed. This suggests that an increase in particle size occurred, 
and therefore, successful ZnS coating of CdSe QDs was achieved as similarly reported 
(Dabbousi et al., 1997 & Pechstedt et al., 2010).  
The narrow and sharp PL peaks depicted that both the CdSe core and CdSe/ZnS core-shell 
QDs had a narrow size distribution. Additionally, literature suggests that the surface 
passivation of the CdSe core with a ZnS coating should result in a higher quantum yield by 
approximately 50 % (Dabbousi et al., 1997). QDs with smaller diameters usually have very 
large surface-to-volume ratios and the presence of surfactants such as TOP are subjected to 
broad deep trap emissions as a result of incomplete surface passivation (Dabbousi et al., 1997 
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& Jones et al., 2003). The ZnS coating should therefore function as a suppressor of these trap 
emissions by passivation of the surface trap sites within the crystalline structure (Dabbousi et 
al., 1997). This in turn produces a PL subjected to band-edge recombination and thus, higher 
quantum yield (Jones et al., 2003).  
It is important to note the wavelengths at which these particles emit light. Green fluorescent 
molecules have emission profiles near 500 nm (Bruchez et al., 1998). The CdSe/ZnS 
core/shell QDs emitted light with a wavelength of ~525 nm, as described in Section 2.4.1. 
. 
2.5.2.3. Transmission electron microscopy 
To directly investigate the size distribution and morphology of QDs, TEM or HR-TEM may 
be employed. For biological applications, the importance of producing QDs with particular 
structural properties would facilitate the ease of functionalising the nanoparticles with 
biomolecule counterparts (Zhang and Clapp, 2011).   
The HR-TEM micrograph for the CdSe/ZnS core-shell QDs is shown in Figure 2.3. The 
micrograph shows that the QDs are relatively monodispersed and spherical in shape. The 
inset of Figure 2.3 demonstrates that poor lattice fringes were resolved, revealing that the 
structural quality of the QDs were not of high quality.  This may be as a result of high lattice 
mismatches between the core and shell materials during the growth phase (Qi, 2001 & Zeng 
et al., 2009).  
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Figure 2.3. High Resolution-TEM micrograph of CdSe/ZnS core-shell QDs. 
 
2.5.2.4. EDS 
Physical characterisation of nanomaterials may be achieved at different levels. To confirm 
the composition of the QDs prepared, the EDS analysis was carried out. The EDS spectrum 
showed the presence of all the four elements, Cd, Se, Zn and S (Figure 2.4). 
After successful characterisation by PL spectroscopy, HR-TEM and EDS, it was 
demonstrated that nearly monodispersed and green fluorescent CdSe/ZnS core-shell QDs 
were synthesised using an organometallic approach. The results obtained were satisfactory 
proven to proceed with ligand exchange to solubilise the QDs for a biological environment.  
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Figure 2.4. EDS spectrum of the as prepared CdSe/ZnS core-shell QDs. 
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2.6. Water soluble CdSe/ZnS core-shell QDs 
2.6.1. Introduction 
The organometallic approach produces QDs stabilised by hydrophobic surfactants and 
therefore an important step is then to ensure that these QDs are rendered water-soluble. This 
may be achieved by surface modification with hydrophilic or ampiphilic moieties that would 
facilitate its application in a biological environment (Zhang and Clapp, 2011). The high-
temperature synthesis lack intrinsic aqueous solubility, subsequently; phase-transfer to an 
aqueous solution is required through one of two strategies, that is, encapsulation or ligand 
exchange. Encapsulation relies on hydrophobic adsorption onto the TOP capped QDs, 
whereas; ligand exchange relies on mass action by means of heterobifunctional ligands that 
serve to displace the hydrophobic surfactant. Examples of such ligands include 3-
mercaptopropionic acid or L-cysteine, whose carboxyl and amine moieties, respectively, 
renders the QD water-soluble (Medintz et al., 2005)  
 
2.6.2. Ligand Exchange 
Ligand exchange approaches reported for L-cysteine capped CdSe/ZnS QDs (Cys-QD) 
generally involved transferring the QDs from the organic phase to the aqueous phase as 
described above, however, the resultant Cys-QDs were only stable for 24 hours. Precipitated 
Cys-QDs were observed as macroscopic aggregates formed as a result of cysteine oxidation, 
consequently forming cysteine dimers (cystine) that are incapable of binding to the QD 
surface (Liu et al., 2007). An alternative capping strategy proposed by Carrillo-Carrion et al., 
produced bio-compatible and more stably dispersed Cys-QDs which showed a decline in 
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fluorescence intensity after 2 days, though the dispersion was stable for at least a month 
(Carrillo-Carrion et al., 2009). 
                                           
Figure 2.5. Ligand exchange using L-Cysteine (a) CdSe/ZnS core-shell QDs 
before sonication and (b) after sonication 
 
Figure 2.5 shows the development of water-soluble Cys-QDs using the method described by 
Carrillo-Carrion et al., described in Section 2.4.3. Prior to sonication, the TOP capped 
CdSe/ZnS core-shell QDs remained in its pelleted form, clearly demonstrating the 
hydrophobicity. However, after sonication (ligand exchange), the Cys-QDs appear well 
dispersed in the aqueous solution, indicative of a successful ligand exchange. The water-
soluble QDs produced in this section were of satisfactory quality to proceed with biological 
application, when characteristically compared to those discussed above by Carrillo-Carrion et 
al., 2009. 
 
 
 
 
(b) (a) 
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Chapter Three: Selective eradication of cancer cells using peptide 
directed QDs to deliver a pro-apoptotic peptide 
 
3.1. Introduction 
The efficiency of any cancer treatment is directly related to and measured by its capacity to 
reduce or eradicate tumours and minimally, if at all damage healthy tissue (Byrne et al., 
2008). Considering this, the therapeutic goal of cancer is to selectively target and kill 
cancerous cells (Haglund et al., 2009 & Sioud and Mobergslien, 2012 & Thundimadathil, 
2012). Conventional chemotherapeutic drugs lack the aforementioned ability as a result of 
non-specific distribution of the drug. Consequently, giving rise to dose-related systematic 
toxicities, thereby, restricting the amount of drug to be administered and in turn leading to 
inadequate therapeutic effects (Allen and Cullis, 2004 & Wang et al., 2009).  For this reason, 
an alternative strategy is required. Nanoparticle delivery systems offer an improved 
alternative due to their ability to interact at the cellular level with a great degree of specificity 
(Byrne et al., 2008 & Singh and Lilard, 2009).  
 
3.2. Objective of this chapter 
The objective of this chapter was to, respectively, bi-conjugate the commercially available 
amino Qdot525 (Qdot525) and the previously synthesised Cys-QDs (Chapter 2) to the 
LTVSPWY (p.L) and Smac peptides. Then carry out a comparative study to relate the 
efficiency of the Cys-QDs to the Qdot525 by evaluating whether the respective QD peptide 
bi-conjugates (Qdot525/p.L+Smac or Cys-QD/p.L+Smac) selectively target and eradicate 
cancer cells.  
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3.3. Materials and suppliers  
2X Trypsin         Life Technologies 
Amino Qdot®525 ITK™       Life Technologies 
BM cyclin          Roche 
Boric acid         Sigma-Aldrich 
Dimethyl sulfoxide (DMSO)       Sigma-Aldrich  
Dulbecco’s Modified Eagles Media (DMEM)     Whitehead Scientific 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) (EDC)   Sigma-Aldrich 
Ethanol          Merck  
Fetal Bovine Serum (FBS)       Biochrome  
Fluoroshield with DAPI       Sigma-Aldrich 
LTVSPWY peptide        Anaspec 
N-acetyl-D-erytho-spinghosine (C2 Ceramide)    Sigma-Aldrich 
Nucblue Live Cell Stain       Life Technologies 
Paraformaldehyde        Sigma-Aldrich 
Penicillin/streptomycin        Whitehead Scientific 
PD-10 purification column       GE Healthcare 
Phosphate buffered saline (PBS)       Whitehead Scientific 
Smac/DIABLO peptide       Anaspec 
Sodium Hydroxide        Merck 
Triton X-100         Sigma-Aldrich 
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3.4. Solutions and buffers  
3% Bovine Serum Albumin (BSA): 0.3 g/ml BSA was prepared in PBS.  
 
3.5. Methods 
3.5.1. Cell culture  
HT29 and HeLa cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM), 
supplemented with 10 % penicillin/streptomycin (Life Technologies) and 10 % Fetal Bovine 
Serum (FBS) (Biochrome). 
 
3.5.2. Thawing of cells 
Vials containing the frozen cells were removed from the -150 
o
C freezer and allowed to thaw 
at room temperature. Cells were then transferred to a 15 ml tube containing 3 ml DMEM and 
the latter transferred into a 25 cm
2
 tissue culture flask. The flask was placed in a water 
jacketed CO2 incubator (Labotec) at 37 
o
C and 5 % CO2 until 60-90 % confluency was 
reached.  
 
3.5.3. Trypsinization of cells  
Once the cells reached the desired confluency, trypsinization was carried out as follows:  
The DMEM in the flask was decanted. Thereafter, the cells were washed with 1 X Phosphate 
buffered saline (PBS). The PBS was then discarded and the cells were trypsinized with the 
addition of 1 X trypsin and incubated in a water jacketed CO2 incubator at 37 
o
C for 2-3 min. 
DMEM was added to the cells to inactivate the trypsin. Cells were collected by centrifugation 
at 3000 x g.  
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3.5.4. Freezing of cells  
Once the cells reached the desired confluency, the cells were removed by trypsinization as 
described above in Section 3.5.3. The cell pellet generated from trypsinization was prepared 
for long-term storage. The cell pellet was resuspended in DMEM containing 10 % DMSO, 
and aliquoted into 2 ml cryo-vials and stored at -150 
o
C.   
 
3.6. Dose response curves 
3.6.1. Seeding of cells 
HT29 cells were cultured and trypsinized as described in Section 3.5.1 and 3.5.3. The cells 
were counted using the Countess Automated Cell Counter (Invitrogen). The cells were 
seeded in to 96-well cell culture plates at a cell density of 1x10
5
 cells/ml. The 96-well cell 
culture plates were placed into a water jacketed CO2 incubator at 37 
o
C for 24 hrs. 
 
3.6.2. QD Treatment  
After 24hrs of culturing, the cells were treated with varying concentrations of QDdot525 
(Invitrogen) or Cys-QD (Chapter 2) for 24 hrs in a water jacketed CO2 incubator at 37 
o
C. 
The treatments were performed in triplicate. After the 24 hrs treatment, the WST-1 Cell 
Proliferation Reagent (10 µl/well) was added to the respective wells. The cells were further 
incubated in a water jacketed CO2 incubator at 37 
o
C. The 96-well cell culture plates were 
agitated for 1 min and absorbance readings were obtained at 440 nm and 620 nm using a 
Spectrophotometer (BMG labotec). 
 
3.7. Bi-conjugation of QDs to peptides 
The reagents as listed in Tables 3.1 and 3.2, were added to a clean amber (light protective) 
glass vial. The reaction mixture was vortexed for 2 hrs at room temperature. Two other 
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conjugations were setup in a similar manner, in the absence of the Smac peptide and used as 
controls. The QD peptide bi-conjugates generated from this reaction were: (1) 
Qdot525/p.L+Smac, (2) Qdot525/p.L, (3) Cys-QD/p.L+Smac and (4) Cys-QD/p.L.  
 
Table 3.1. Bi-conjugation of the Qdot525 to the p.L and Smac peptides 
Qdot525/p.L+Smac Qdot525/p.L Stock 
concentration 
Final concentration 
Borate Buffer (pH 
8.5) 
Borate Buffer (pH 
8.5) 
50mM 50 mM 
Amino-Qdot525 Amino-Qdot525 8 µM 0.25 µM 
p.L peptide p.L peptide 11595 µM 50 µM 
Smac peptide - 10602 µM 50 µM 
EDC EDC 50 µM 0.375 µM 
 
Table 3.2. Bi-conjugation of the Cys-QD to the p.L and Smac peptides 
Cys-QD/p.L+Smac Cys-QD/p.L Stock 
concentration 
Final concentration 
Borate Buffer (pH 
8.5) 
Borate Buffer (pH 
8.5) 
50mM 50 mM 
Cys-QD Cys-QD 14400 µg/ml 350 µg/ml 
p.L peptide p.L peptide 11595 µM 50 µM 
Smac peptide - 10602 µM 50 µM 
EDC EDC 50 µM 0.375 µM 
 
 
3.8. Desalting of the QD peptide bi-conjugates by gel filtration 
The bi-conjugates were subjected to purification using the PD10 desalting column (GE 
Healthcare) according to the manufacturer’s instructions: 
 
The cap at the bottom of the column was removed and the column storage solution was 
poured off. The sealed end of the column was cut off. The column was then equilibrated by 
addition of the equilibration buffer (Borate buffer, pH 8.5). The buffer was allowed to 
migrate into the column bed and the flow through was discarded. This was repeated four 
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times. The QD-peptide bi-conjugates were added to the respective columns. The QD-peptide 
bi-conjugates were allowed to migrate into the column bed. The volume was adjusted to 2.5 
ml, by addition of the equilibration buffer. The buffer was then allowed to migrate into the 
column bed. The flow through was discarded. Clean glass vials were placed under the 
columns for sample collection. The bi-conjugates were collected by addition of the elution 
buffer (1 X PBS, pH 7.4) at 1000 µl elutes. Aliquots of 100 µl were placed into PCR tubes. 
An aliquot (100 µl) of the unconjugated QD samples (Qdot525 and Cys-QDs) were included 
as controls. Images were captured under UV-light (UVP) and the desalted bi-conjugates were 
stored at 4 
o
C until further use. 
 
3.9. Immunocytochemistry 
3.9.1. Seeding of cells 
HT29 and HeLa cells were cultured and trypsinized as described in Section 3.5.1 and 3.5.3. 
The cells were counted using the Countess Automated Cell Counter (Invitrogen). The cells 
were seeded onto sterilised coverslips in 6-well cell culture plates at a cell density of 2 x 10
5
 
cells/ml. The 6-well cell culture plate was placed in a water jacketed CO2 incubator at 37 
o
C 
and the cells cultured until 50 – 60 % confluency.  
 
3.9.2. Fixation and permeabilisation  
Once the cells reached the desired confluency, the media was removed from the cells in 6-
well cell culture plates using a pipette. The cells were washed twice with 1 X PBS. The PBS 
was then discarded and 4 % formaldehyde was added to each well and left for 20 min at room 
temperature to allow cells to fix to the coverslips. The PBS was then discarded and 0.1 % 
Triton X-100 was added to each well and left for 5 min to allow permeabilisation of the cell 
membrane. This was followed by washing the cells twice with 1 X PBS. 
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3.9.3. Fixed cell staining 
The washed cells were then incubated with the respective QD peptide bi-conjugates: 
Qdot525/p.L+Smac, (2) Qdot525/p.L, (3) Cys-QD/p.L+Smac and (4) Cys-QD/p.L for 1 hr at 
room temperature. A drop of Fluoroshield DAPI mounting media (Sigma-Aldrich) was 
placed onto labelled microscope slides. The cells were washed 3 times with PBS and dried by 
blotting the edges of the coverslip on paper towel. The coverslips were transferred onto the 
mounting media with the cell-side faced down. The images were captured at 100 X 
magnification under oil immersion using the fluorescent Carl Zeiss LSM 780 Confocal 
microscope with Elyra S.1 super resolution platform (Carl Zeiss).  
 
3.9.4. Live cell staining 
Cells were seeded as described in Section 3.9.1. Once the cells reached the desired 
confluency, the media was removed from cells in 6-well cells culture plates using a 
serological pipette. The cells were washed twice with 1 X PBS.  The PBS was then discarded 
and the cells were incubated with the respective QD peptide bi-conjugate for 24 hrs in a water 
jacketed CO2 incubator at 37 
o
C. The staining medium was then removed using serological 
pipette and the cells were washed four times with 1 X PBS. The cells were then fixed as 
described in Section 3.9.2. A drop of Nucblue Live Cell Stain was placed onto labelled 
microscope slides and the cells were mounted and visualised as described in Section 3.9.3. 
 
3.10. Cytotoxicity assay 
HT29 and HeLa cells were seeded as described in Section 3.9.1. After 24 hrs of culturing, the 
cells were treated with the respective QD peptide bi-conjugates (Section 3.7) in the presence 
or absence of ceramide (60 µM) for 24 hrs in a water jacketed CO2 incubator at 37 
o
C. The 
treatments were performed in triplicate. After the 24 hr treatment, WST-1 Cell Proliferation 
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Reagent (10 µl/well) was added to the respective wells. The cells were further incubated for 2 
hrs in a water jacketed CO2 incubator at 37 
o
C. The 96-well cell culture plates were agitated 
for 1 min and analysed using a spectrophotometer (BMG labotec).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 | P a g e  
 
3.11. Results and Discussion 
3.11.1. Dose response curves to determine optimal QD concentration 
To determine a good response model for the drug delivery system, a non-hazardous dosage of 
the QDs must be obtained. Therefore using a dose response curve, the lethal concentration at 
~50 % (LD50) of the QDs and the appropriate, non-hazardous concentration of the QDs 
required for application in the QD peptide bi-conjugate can be extrapolated. Since the aim of 
the targeted drug delivery system developed in this study is to sensitise the cells to treatment 
with ceramide, it is important to ensure that the QDs do not induce toxicity. To accomplish 
this, HT29 cells were seeded and treated as described in Sections 3.6.1 and 3.6.2. Figure 3.1 
shows the dose response curves for HT29 cells after the 24 hr treatment.  
Cellular viability was assessed using the WST-1 Cell Proliferation (Roche) colometric assay. 
Figure 3.1 illustrates that a decrease in cell viability is directly proportional to an increase in 
QD concentration for both the Qdot525 and the Cys-QDs. The LD50 values obtained were 
~0.8 µM and ~720 µg/ml for Qdot525 and Cys-QDs, respectively. Based on this dose 
response curve, it was decided to use a concentration below the LD50, 0.25 µM and 350 
µg/ml for the Qdot525 and Cys-QDs, respectively. 
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Figure 3.1. Dose response curve of the Qdot525 (A) and Cys-QDs (B). HT29 cells were subjected to treatment with the Qdot525 
or the Cys-QD for 24 hrs. Subsequently, the cell viability was determined using the WST-1 Cell Proliferation colometric assay. The 
data was obtained in triplicate and used to construct dose response curves for the respective QDs (mean ± SD; n=3).  
 
 
0
10
20
30
40
50
60
70
80
90
100
0uM 0.25uM 0.5uM 1uM
%
 C
e
ll 
V
ia
b
ili
ty
 
Qdot525 concentration  
0
10
20
30
40
50
60
70
80
90
100
0ug/ml 250ug/ml 500ug/ml 1000ug/ml
%
 C
e
ll 
V
ia
b
ili
ty
 
Cys-QD concentration 
LD50=~0.8 µM 
LD50=~720 µg/ml 
B A 
 
 
 
 
69 | P a g e  
 
N 
N 
  
QD  
H 
  
NH
2 
– LTVSPWY 
O 
  
H 
  
O 
  
NH
2 
– AVPIAQSE H
2
N 
H
2
N 
H
2
N 
H
2
N 
H
2
N 
QD  
EDC 
2 hrs 
NH
2 
– LTVSPWY – OH 
NH
2 
– AVPIAQSE– OH 
  
3.11.2. Bi-conjugation of QDs to peptides using EDC chemistry 
The specificity of a nanoparticle-based drug delivery system can be achieved by cancer 
specific peptides; owing to its high-affinity sequences that are easy to conjugate to its’ 
counterparts. Furthermore, its’ small size that permits a good degree of tissue penetrability 
and drug carrying capacity, negligible immunogenicity; and a considerable level of in vivo 
stability (Jaracz et al., 2005 & Li and Cho, 2012). In order to facilitate the use of a drug 
delivery system, the respective moieties are required to be chemically linked (Hermanson, 
2013). EDC is cross-linker most often employed to mediate the bi-conjugation of amino and 
carboxylate groups (Zhang and Clapp, 2011 & Vashist, 2012).  
The objective of this section was to generate four bi-conjugates, namely, (1) 
Qdot525/p.L+Smac, (2) Qdot525/p.L, (3) Cys-QD/p.L+Smac and (4) Cys-QD/p.L. This was 
achieved using EDC chemistry as described in Section 3.6 and schematically illustrated in 
Figure 3.2.  
 
 
Figure 3.2. Schematic diagram illustrating cross-linking of amine 
functionalised QDs with p.L and Smac. EDC activates the carboxylate groups 
present on the peptides and in the presence of the amine functionalised QDs, a 
covalent bond is formed.  
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3.11.3. Desalting of the bi-conjugates using gel filtration 
The bi-conjugates prepared in Section 3.7 were then subjected to desalting using the PD10 
gel filtration column (GE Healthcare) as described in Section 3.8.  The objective of this 
section was to determine which fraction contained the QD peptide bi-conjugate. This was 
determined by comparing the fluorescence intensities of the various elutes, as demonstrated 
in Figure 3.3.   
 
 
 
            
Figure 3.3. Desalted QD peptide bi-conjugates. In (A) Qdot525 peptide bi-
conjugates and (B) Cys-QD peptide bi-conjugates, Lane 1 represent the 
unconjugated QDs. Lanes 2 and 3 represent elutes 1 and 2, respectively for the 
QD/p.L bi-conjugates. Lanes 4 and 5 represent elutes 1 and 2, respectively for the 
QD/p.L+Smac bi-conjugates. Images were captured using the UVP system.  
 
The unconjugated Qdot525 sample showed the highest fluorescence. This was expected, 
since these QDs were in a more concentrated form. The Qdot525/p.L and Qdot525/p.L+Smac 
elute 2 had a higher fluorescence intensity than that of their elute 1 counterparts. This 
suggests that elute 2 contained most of the Qdot525 peptide bi-conjugates. The unconjugated 
Cys-QDs fluorescent signal was not as bright as that of the unconjugated Qdot525 sample. 
Contrary to the Qdot525 peptide bi-conjugates, the Cys-QD/p.L elute 1 had a higher 
     1     2             3          4            5     1     2           3           4            5 
 
 
 
 
71 | P a g e  
 
fluorescent signal than that of Cys-QD/p.L elute 2, suggesting that more of the Cys-QD 
peptide bi-conjugates were present in this fraction. Overall, the Cys-QD had a very poor 
fluorescent signal which may be accounted for by low concentrations (350 µg/ml) used in the 
bi-conjugation reactions. Nonetheless, the presence of a fluorescent signal in multiple 
fractions, confirmed the presence of the QDs, therefore, suggesting the presence of the QD 
peptide bi-conjugates. Based on the fluorescence intensities of the various fractions observed 
in Figure 3.3, elute 2 for the Qdot525 peptide bi-conjugates and elute 1 for the Cys-QD 
peptide bi-conjugates were used for further experiments. 
 
3.11.4. Evaluating the cytotoxicity of the QD bi-conjugate targeted delivery system using 
the WST-1 Cell Proliferation assay 
The objective of this section was to evaluate the cytotoxicity of (1) Qdot525/p.L+Smac and 
(2) Cys-QD/p.L+Smac by combinatorial treatment with ceramide. This was achieved by 
seeding and treating the cells as described in Section 3.9.1 and 3.9.2.  
 
 
 
 
  
 
 
      
Figure 3.4. Evaluating the cytotoxicity of the targeted drug delivery system. HT29 and HeLa cells were subjected to treatment 
with the Qdot525 peptide bi-conjugate or the Cys-QD peptide bi-conjugate in the presence or absence of ceramide for 24 hrs. 
Subsequently, the cell viability was analysed using the WST-1 colometric assay. The data was obtained in triplicate and used to 
construct dose response curves for the respective QDs (mean ± SD; n=3). Error bars represent calculated standard error of the means.    
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Figure 3.4 shows the cytotoxic profile of the respective QD/p.L+Smac bi-conjugates. The 
Qdot525/p.L+Smac bi-conjugate did not enhance the apoptotic effect of ceramide. On the 
contrary, a degree of cytoprotection or anti-apoptotic effect was observed for HT29 cells as 
illustrated by the 20 % increase in cell viability conferred by the Qdot525/p.L+Smac bi-
conjugate (65 % cell viability) as compared to the ceramide only control (45 % cell viability). 
It is possible that the Qdot525 peptide bi-conjugates interacted with ceramide and induced an 
inhibitory effect on ceramide induced apoptotic signalling because the Qdot525/p.L+Smac 
bi-conjugate failed to induce statistically significant cell death when treated without ceramide 
(86 % cell viability). The cytoprotective effect observed may also be due to insufficient 
concentrations of the Smac peptide. This may be as a result of a poorly controlled 
conjugation setup in that, there may have been competitive conjugation between the p.L and 
Smac peptides for the amine groups present on the QD surface, potentially resulting in 
insufficient quantities of the Smac peptide being conjugated to the QD peptide bi-conjugate. 
Smac has been reported to exert its inhibitory effects on XIAP by interaction with its BIR3 
domain (Arnt et al., 2002 & Fandy et al., 2008), therefore, with the possibility that an 
insufficient concentration of Smac being used, may have resulted in suboptimal inhibitory 
action on XIAP; subsequently, low levels of caspase 3 displacement occurred and therefore, 
no synergistic anti-cancer activity was observed.  
 
Under the same conditions, HeLa cells appear to be more susceptible to ceramide induced 
cell death (10 % cell viability) as compared to HT29 cells (45 % cell viability). However, 
again an inhibitory effect was observed when treated with the Qdot525/p.L+Smac bi-
conjugates and ceramide (31 % cell viability). Therefore, suggesting that the Qdot525 
targeted drug delivery system together with ceramide failed to induce a synergistic anti-
cancer effect.   
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There were no statistically significant differences observed between the Cys-QD/p.L+Smac 
bi-conjugate (45 % cell viability) and the ceramide only control (36 % cell viability) for 
HT29 cells. Since the Cys-QDs surface chemistry is different from that of the Qdot525, in 
that there is no polymer coating, the potential interaction observed for the QD525/p.L+Smac 
bi-conjugate may be absent in Cys-QD/p.L+Smac bi-conjugate. Therefore, no cytoprotection 
was conferred in HT29 cells. Under the same conditions, HeLa cells showed more 
susceptibility to ceramide only induced cell death (12 % cell viability) as compared to HT29 
cells (36 % cell viability). There were no statistically significant differences in the response 
of HeLa cells to the treatment with ceramide and the Qdot525/p.L+Smac bi-conjugate (31 % 
cell viability) as well as the Cys-QD/p.L+Smac bi-conjugate (45 % cell viability). The 
general observations for the HeLa cell line were greater susceptibly to cell death induced by 
the Qdot525/p.L+Smac and Cys-QD/p.L+Smac in the presence and absence of ceramide. 
This may be explained by the fact that a dose response trial was not carried out for HeLa cells 
and thus, the LD50 for this cell line may have been lower.  
 
In a study carried out by Fandy et al., it was demonstrated that the level of IAP expression in 
various tumour types determines how the cancer cells will respond to the Smac peptide. The 
N-terminal Smac peptide was only able to sensitise low expressing IAP cancer cells; whereas 
it was able to induce apoptosis in high expressing IAP cancer cells (Fandy et al., 2008). 
Furthermore, Emjedi et al., showed that HT29 and HeLa cells are low expressing XIAP cell 
lines (Emjedi et al., 2013), therefore, it is possible that the expression level of IAPs in HT29 
cells were insufficient to induce sensitising to apoptosis and consequently, no synergistic 
anti-cancer activity was observed. In this instance, the targeted drug delivery system 
developed in this study will prove to be ineffective.  
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Alternatively, it is known that the targeting function of the Smac peptide is elicited by the 
first four amino acids at its N-terminal (Wu et al., 2000 & Gao et al., 2007 & Martinez-Ruiz 
et al., 2008) and thus, the seemingly poorly controlled bi-conjugation setup in this study may 
have resulted in the bi-conjugation of the Smac peptide (N-terminal) to the p.L peptide (C-
terminal), produced by EDC chemistry. The aim of using EDC chemistry was to exclude 
potential cross-reactivity by producing directly complexed QD peptide bi-conjugates 
(Herman, 2008); however, since EDC serves to complex any available carboxylic group to 
any available amine group, the possible peptide-peptide (p.L-Smac) product may have 
instigated an obstruction at the binding site of the Smac peptide, rendering Smac inactive. 
Therefore, the use of an alternative bi-conjugation scheme or the incorporation of a linker 
sequence (Fandy et al., 2008) may produce Qdot525/p.L+Smac or Cys-QD/p.L+Smac bi-
conjugates that are able to enhance the ceramide induced cell death. 
 
 
3.11.5. Evaluating the binding affinity of the QD peptide bi-conjugates 
The objective of this section was to assess and compare the binding affinity of (1) the 
Qdot525 peptide bi-conjugates and (2) Cys-QD peptide bi-conjugates to HT29 and HeLa 
cells. To undertake this, HT29 and HeLa cells were cultured and seeded as described in 
Section 3.5.1 and 3.5.3. Since the QDs offer good fluorescent properties, the QDs were used 
to quantify the fluorescence intensity, indicative of the QD peptide bi-conjugate binding to 
the cells.  
 
Figure 3.5 and 3.6 shows the binding of the Qdot525 peptide bi-conjugates and the Cys-QD 
peptide conjugates to HT29 and HeLa cells, respectively. There were no significant 
differences between the manner in which the unconjugated QDs and the respective QD 
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peptide bi-conjugates stained the cells. Firstly, this data suggests that the untargeted QDs are 
able to penetrate the cellular membrane, which is in agreement with Cho et al., who reports 
that the cellular uptake of free nanoparticles are attributed to their small size range and 
therefore permits internalisation of nanoparticles with great ease (Cho et al., 2008). Secondly, 
this data suggests that selective targeting was not achieved. EDC served to directly complex 
the QD peptide bi-conjugates (Herman, 2008); however, the results suggest that this may not 
have been an appropriate method of bi-conjugation.  
 
The targeting function of the p.L peptide may have been elicited by its C-terminal and thus, 
the close proximity of the QDs to the p.L peptide, produced by EDC, may have resulted in 
the loss of the p.L peptide’s ability to target the erbB-2 receptor. Therefore, the use of an 
alternative bi-conjugation scheme or the incorporation of a linker sequence may produce a bi-
conjugate that is able to target efficiently. From the literature, very efficient targeting using 
the p.L peptide has been demonstrated; an example of this was reported by Jie et al, (2012) 
who used EDC bi-conjugation chemistry. However, to ensure more efficient targeting devoid 
of interference with the binding affinity and specificity, the p.L peptide was PEGylated (Jie et 
al., 2012).   
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Figure 3.5. Binding of the Qdot525 peptide bi-conjugates. (A) HT29 and (B) HeLa cells were incubated with the respective 
Qdot525 peptide bi-conjugates for 1 hr and then counterstained with DAPI. Subsequently, the cells were examined under a confocal 
laser scanning microscope. Representative micrographs illustrate binding of the Qdot525 peptide bi-conjugates (green) and nuclei 
localisation (blue) in both cell lines. Images were captured at 100X magnification. 
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Figure 3.6. Binding of Cys-QD peptide bi-conjugates. (A) HT29 and (B) HeLa cells were incubated with the respective Cys-QD 
peptide bi-conjugates for 1 hr and then counterstained with DAPI. Subsequently, the cells were examined under a confocal laser 
scanning microscope. Representative micrographs illustrate binding of the Cys-QD peptide bi-conjugates (green) and nuclei 
localisation (blue) in both cell lines. Images were captured at 100X magnification. 
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Alternatively, the poor selectively presented by the p.L peptide in this study may be 
explained by the possibility that the bi-conjugation may have been unsuccessful. This would 
explain why there were no significant differences observed by the manner in which the 
unconjugated QDs and the QD peptide bi-conjugates stained the cells. Using tools such as PL 
spectroscopy and EDS, it may be possible to show that a successful bi-conjugation occurred. 
PL uses the principle of exposing the sample to light and the PL (emitted light) gets 
stimulated by a higher energy, producing an emission spectrum that may be analysed 
computationally (Seyhan, 2003). Any red shifted emissions from that of the unconjugated 
QDs would communicate an increase in the QD diameter and therefore, suggest the presence 
of the peptide on the QD surface and in turn, a successful bi-conjugation. EDS relies on the 
generation of a unique x-ray spectrum produced by the unique atomic structure ascribed to 
every element. Therefore, the presence of any biological materials in an elemental analysis by 
EDS would suggest the bi-conjugation of the QDs to the peptides. 
 
3.11.6. Evaluating the internalisation of the bi-conjugates using live cell 
immunocytochemistry  
The literature reports the p.L peptide being able to internalise erbB-2 positive breast cancer 
cells (Sioud and Mobergslien, 2012). Since HT29 cells have high expression levels of the 
erBb-2 receptor, the objective of this section is to determine whether the p.L peptide also 
internalises HT29 cells.  
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Figure 3.7. Internalisation of the Qdot525 peptide conjugates. (A) HT29 and (B) HeLa cells were incubated with the respective 
Qdot525 peptide bi-conjugates for 24 hrs and then counterstained with Nucblue. Subsequently, the cells were examined under a 
confocal laser scanning microscope. Representative micrographs illustrate efficient cellular uptake of the Qdot525 peptide bi-
conjugates (green) and nuclei localisation (blue) in both cell lines. Images were captured at 100X magnification. 
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Figure 3.8. Internalisation of the Cys-QD peptide conjugates. (A) HT29 and (B) HeLa cells were incubated with the respective 
Cys-QD peptide bi-conjugates for 24 hrs and then counterstained with Nucblue. Subsequently, the cells were examined under a 
confocal laser scanning microscope. Representative micrographs illustrate efficient cellular uptake of the Cys-QD peptide bi-
conjugates (green) and nuclei localisation (blue) in both cell lines. Images were captured at 100X magnification. 
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Figures 3.7 and 3.8 show the internalisation of the QD peptide bi-conjugates in HT29 and 
HeLa cells. There were no significant differences observed between the manner in which the 
unconjugated Qdot525 and the Qdot525 peptide bi-conjugates as well as the Cys-QD and 
Cys-QD peptide bi-conjugates stained the HT29 cells. This correlates with the fixed cell 
immunocytochemistry data (Figure 3.5 and 3.6) suggesting that selective targeting was not 
achieved. This may be due to an unsuccessful bi-conjugation, suggesting that what essentially 
is being observed is the staining of unconjugated QDs in all three instances (unconjugated 
QD or QD/p.L or QD/p.L-Smac) instead of the expected QD peptide bi-conjugates. 
Therefore, it would be advisable to establish whether the bi-conjugation in this study has 
been successful using the techniques previously discussed. 
 
Of note, the Qdot525 peptide bi-conjugates were very efficiently taken up by HeLa cells as 
well. This may be explained by the reason that PEGylated QDs assists with escape from 
endosomal trapping (Choi et al., 2011) resulting in no difference in the manner in which the 
different cell lines internalised the Qdot525 peptide bi-conjugates due to PEGylation of the 
Qdot525. This in turn explains why the Cys-QD peptide bi-conjugates showed much higher 
fluorescence intensity in HT29 cells as compared to that of HeLa cells, indicative of very 
efficient internalisation to HT29 cells since the Cys-QDs were not synthesised with any 
polymer coating. To fairly evaluate the uptake of the QD peptide bi-conjugates developed in 
this study, QDs with the exact chemistry should be used.  
 
The data from this section demonstrated efficient uptake of the QD peptide bi-conjugates, 
however, no selective targeting to HT29 cells were observed; this may be attributed to the 
previously discussed factors explained in Section 3.11.5. This data also corroborates results 
obtained for the cytotoxicity assay, in that the QD peptide bi-conjugates were not 
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successfully conjugated and therefore, no enhanced ceramide induced cell death was 
observed in the presence of the Qdot525/p.L+Smac or Cys-QD/p.L+Smac bi-conjugates and 
in fact, what was observed as no enhanced anti-cancer activity in Figure 3.4 is representative 
of unconjugated QDs in each instance where the Qdot525/p.L+Smac or Cys-QD/p.L+Smac 
bi-conjugates were expected to be internalised.  
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Summary of this study 
4.1. General Discussion  
Cancer is a leading cause of death, worldwide. It is a progressive disease, in that 
accumulative changes occur at the genetic level. Subsequently, presenting a disease that is 
complex and life-threatening (Pal and Nayak, 2010). Annual projections are expected to 
reach approximately 16 million new mortality cases by 2020 (Thundimadathil, 2012). These 
statistics suggest that current therapeutic strategies appear to be less effective and therefore 
presenting a need for alternative therapeutic approaches (Sumer and Gao, 2008).  
The non-specific distribution of conventional chemotherapeutic drugs, imposes severe 
toxicities, thereby restricting the drug dosages that may be administered (Wang et al., 2009). 
Overall, the objective is to produce an effective treatment, which directly targets and kills the 
cancerous cells, with little to no damage inflicted on healthy cells (Brannon-Peppas and 
Blanchette, 2004 & Byrne et al., 2008).  In view of this, the therapeutic goal of chemotherapy 
has shifted towards targeted drug delivery systems; which have successfully been 
demonstrated using cancer specific peptides (Byrne et al., 2008 & Haglund et al., 2009 & 
Sioud and Mobergslien, 2012 & Thundimadathil, 2012). In particular, the p.L peptide that has 
been shown to successfully target several erbB-2 positive cancer cells (Shadidi and Sioud, 
2002 & Shadidi and Sioud, 2003 & Wang et al., 2007 & Haglund et al., 2009 & Jie et al., 
2012).  
 
Additionally, the application of apoptosis inhibitory peptides as potential therapeutic 
modalities in targeted drug delivery systems have been reported (Shadidi and Sioud, 2003). 
Smac/DIABLO is a pro-apoptotic peptide that is able to interact with IAPs, thereby inducing 
pro-apoptotic signalling (Wu et al., 2000). It has been demonstrated in literature that 
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Smac/DIABLO and N-terminal Smac-derived short peptides enhance the anti-cancer activity 
of several drugs that induce apoptosis in cancer cells (Chai et al., 2000 & Arnt and 
Kaufmann, 2003 & Martinez-Ruiz et al., 2008 & Lu et al., 2011).  
Nanotechnology has emerged as a promising avenue to formulate appropriate and efficient 
drug carriers for targeted drug delivery systems (Cao and Wang, 2011). Several nanoparticles 
have successfully been used in cancer treatment, of which QDs served as a delivery vehicle 
and imaging agent (Drbohlavova et al., 2009).  
QDs are fluorescent semiconductor colloidal crystalline nanoparticles with diameters, 
generally, ranging between 2-10 nm in size (Chan et al., 1998 & Mattheakis et al., 2004) and 
are widely being applied as imaging agents (Resch-Genger et al., 2008). The unique 
properties exhibited by QDs are attributed to their physicochemical characteristics and 
therefore in the advent of synthesising these nanoparticles, determining what these 
characteristics are and how it plays a vital role in understanding its behaviour and subsequent 
application in biological systems (Zhang and Clapp, 2011).  
The objective of this study was to develop a multimodal nanoparticle-based targeted drug 
system using peptide directed QDs as an imaging agent and delivery vehicle to selectively 
kill cancer cells using the pro-apoptotic peptide, Smac in combinatorial treatment with 
ceramide. To achieve this, highly monodispersed and green emitting fluorescent CdSe/ZnS 
core-shell QDs were synthesised using an organometallic approach. PL spectroscopy 
illustrated that the as prepared CdSe/ZnS core-shell QDs had a narrow and sharp PL 
spectrum, indicative of a narrow size distribution. Additionally, wavelength emissions at 525 
nm were observed and therefore, suggesting green fluorescent QDs were obtained. High 
resolution TEM micrographs confirmed that monodispersed and spherical shaped QDs were 
synthesised, however, poor lattice fringes were observed, indicative of poor structural quality 
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QDs. The EDS analysis revealed that all four elements, Cd, Se, Zn and S were present in the 
as prepared QDs. The abovementioned data proved satisfactory to proceed with ligand 
exchange to solubilise the QDs for biological application. Water-soluble L-cysteine capped 
CdSe/ZnS core-shell QDs (Cys-QDs) were obtained using the method described by Carillo-
Carrion et al., 2009. This was established by observing the well-dispersed QDs in the 
aqueous solution, indicative of a successful ligand exchange.  
The in-house synthesised Cys-QDs and commercially available Qdot525, with similar 
chemistry, were used comparatively in the development of p.L peptide directed QDs 
functionalised with Smac. A non-hazardous dosage of the respective QDs was obtained using 
a dose response curve. Based on the response of HT29 cells to treatment with the QDs, it was 
decided to use a concentration below the LD50, that is, 0.25 µM and 350 µg/ml for the 
Qdot525 and Cys-QDs, respectively. Using the aforementioned concentrations, the QDs were 
bi-conjugated to the p.L peptide and Smac peptide using EDC chemistry. This was followed 
by desalting the QD peptide bi-conjugates (Qdot525-p.L-Smac or Cys-QD-p.L-Smac) using 
PD10 gel filtration columns and the fractions with the highest fluorescence intensities were 
used for subsequent experiments. The potential cytotoxicity of the targeted drug delivery 
system developed in this study was then evaluated using the WST-1 Cell Proliferation assay. 
It was found that the combinatorial treatment of the Qdot525/p.L+Smac and the Cys-
QD/p.L+Smac bi-conjugates did not enhance nor sensitise HT29 and HeLa cells to ceramide 
induced cell death. This may be explained by several factors, such as (1) insufficient 
concentration of Smac being used, resulting in suboptimal inhibitory action on XIAP or (2) a 
potential obstruction at the binding site of the Smac peptide possibly caused by bi-
conjugating the peptides to each other or (3) the low expression levels of XIAP in these 
particular cell lines failed to sensitise the cells to apoptosis. This was confirmed when the 
binding affinity and internalisation of the QD peptide bi-conjugates were evaluated using 
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immunocytochemistry. No selective targeting to HT29 cells was observed, however, a degree 
of internalisation was achieved. Despite internalisation, there were no significant differences 
between the manner in which the respective QD peptide bi-conjugates were taken up by 
HT29 and HeLa cells. This was not anticipated since the literature reports that HT29 and 
HeLa cells retain high and low expression levels of the erbB-2 receptor, respectively 
(Kavanagh et al., 2009). It is possible that the p.L peptide lost functionality due to the method 
of bi-conjugation. Additionally, the bi-conjugation may have been unsuccessful and 
therefore, no targeting was observed due to the absence of the targeting moiety.  
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4.2. Conclusion 
The objective of this study was to develop a multimodal nanoparticle-based targeted drug 
system using peptide directed QDs as an imaging agent and delivery vehicle to selectively 
kill cancer cells using the pro-apoptotic peptide, Smac in combinatorial treatment with 
ceramide. Green fluorescent CdSe/ZnS core-shell QDs were successfully synthesised and 
solubilised for its application in a biological environment. This study suggests that the bi-
conjugation strategy may have been unsuccessful as demonstrated by no selective targeting to 
HT29 cells. Additionally, the possibility of an inappropriate bi-conjugation strategy resulted 
in the ineffective combinatorial treatment of the QD peptide bi-conjugate and consequently, 
HT29 cells were not sensitised to ceramide induced cell death. Although the overall objective 
was not met, the efficiency of the in-house synthesised Cys-QDs in comparison to the 
commercially available Qdot525 was observed to be of good quality and therefore, may 
potentially be used in other biological applications.  
 
4.3. Future work 
Future directions would aim to address limitations identified in this study. Over time, L-
cysteine forms dimers and renders the QDs insoluble in aqueous medium, thus alternative 
water soluble capping ligands may be investigated to produce water-soluble QDs that are 
stable for longer.  The literature clearly demonstrates the targeting ability and apoptotic 
sensitising of the p.L peptide and Smac peptide, respectively. Therefore, the ineffective target 
drug delivery system developed in this study suggests that an unsuccessful bi-conjugation 
occurred, therefore, exploring alternative bi-conjugation strategies, such as the incorporation 
of a linker sequence to avoid the potential loss of the peptide function may be investigated. 
Finally, the current targeted drug delivery system should be tested on cell lines with different 
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levels of XIAP expression to evaluate if the conditions under which this system was 
developed may prove to be effective.  
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